ANI Pharmaceuticals director proposes $386K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ANI Pharmaceuticals Inc. (ANIP) director and officer Nikhil Lalwani filed a notice covering a proposed sale of 5,400 common shares, with an aggregate market value of $385,776.00 and an approximate sale date of November 16, 2026. The shares were acquired from the issuer as restricted stock awards on March 7, 2026. The notice lists three prior 5,400-share sales on August 25, September 15 and October 15, reported as 10b5-1 sales; the plan adoption date was May 26, 2026.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Restricted Stock Awards financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What earlier ANIP sales by Nikhil Lalwani are listed?
AI-generated analysis. How Rhea-AI works. Not financial advice.